Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KORU Medical Systems (KRMD) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for KORU Medical Systems (KRMD) over the last 11 years, with Q3 2025 value amounting to $8.5 million.

  • KORU Medical Systems' Cash & Equivalents fell 388.69% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 388.69%. This contributed to the annual value of $9.6 million for FY2024, which is 1655.86% down from last year.
  • Latest data reveals that KORU Medical Systems reported Cash & Equivalents of $8.5 million as of Q3 2025, which was down 388.69% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, KORU Medical Systems' Cash & Equivalents peaked at $26.8 million during Q1 2021, and registered a low of $8.1 million during Q2 2025.
  • In the last 5 years, KORU Medical Systems' Cash & Equivalents had a median value of $11.7 million in 2023 and averaged $15.3 million.
  • As far as peak fluctuations go, KORU Medical Systems' Cash & Equivalents skyrocketed by 26047.22% in 2021, and later tumbled by 4585.32% in 2023.
  • Over the past 5 years, KORU Medical Systems' Cash & Equivalents (Quarter) stood at $25.3 million in 2021, then plummeted by 31.29% to $17.4 million in 2022, then crashed by 34.04% to $11.5 million in 2023, then dropped by 16.56% to $9.6 million in 2024, then fell by 11.66% to $8.5 million in 2025.
  • Its Cash & Equivalents was $8.5 million in Q3 2025, compared to $8.1 million in Q2 2025 and $8.7 million in Q1 2025.